The ne plus ultra for deep BCR-ABL sequencing?

The article discusses a study which describes ultra-deep sequencing's (USD) benefits compared with conventional Sanger sequencing in terms of detecting BCR-ABL kinase domain mutations. It reveals that the study could be a help to improve the treatment for resistant patients with chronic myeloid leukemia and acute lymphoblastic leukemia. Information about tyrosine kinase inhibitor (TKI) imatinib is provided.